Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
- Resource Type
- Article
- Authors
- Hollebecque, Antoine; Kuboki, Yasutoshi; Murciano-Goroff, Yonina R.; Yaeger, Rona; Cassier, Philippe Alexandre; Heist, Rebecca Suk; Fujiwara, Yutaka; Deming, Dustin A.; Ammakkanavar, Natraj; Patnaik, Amita; Shimizu, Toshio; Call, Justin; Han, Sae-Won; Fink, Aaron Alan; Chen, Aaron; Willard, Melinda D; Balar, Arjun Vasant; Koyama, Takafumi
- Source
- Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p94-94, 235p
- Subject
- Language
- ISSN
- 0732183X